UNIVERSITAT DUISBURG-ESSEN;UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
发明人:
SCHADENDORF, DIRK,PASCHEN, ANNETTE,LUBCKE, SILKE,FATHO, MARTINA,EBERTS, DANIELA,ECHCHANNAOUI, HAKIM,LENNERZ, VOLKER,WOLFEL, CATHERINE,WOLFEL, THOMAS
申请号：
CA2894966
公开号：
CA2894966A1
申请日:
2013.12.16
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
The present invention relates to novel tumor-associated antigens,which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells,which are specifically reactive to the antigens of the invention in an MHC-independent manner.
